Murepavadin

Murepavadin

Murepavadin (also known as POL7080) is a novel antibiotic specifically designed to target and kill Pseudomonas aeruginosa, a type of bacteria that is a common cause of infection in people with weakened immune systems. It is the first in a new class of antibiotics known as Outer Membrane Protein Targeting Antibiotics (OMPTA).

Mechanism of Action

Murepavadin works by binding to a specific protein on the outer membrane of P. aeruginosa called LptD. This protein is essential for the bacteria's survival as it transports lipopolysaccharides (LPS) to the outer membrane. By binding to LptD, Murepavadin disrupts this process, leading to the death of the bacteria.

Clinical Trials

Murepavadin has undergone several clinical trials to assess its safety and efficacy. In a Phase II clinical trial, it was found to be effective in treating patients with ventilator-associated pneumonia caused by P. aeruginosa. However, a Phase III trial was halted early due to an increased rate of acute kidney injury in patients treated with Murepavadin.

Future Development

Despite the setback in the Phase III trial, research into Murepavadin continues. Scientists are investigating ways to reduce the risk of kidney injury, potentially through dose adjustments or by developing new formulations of the drug.

See Also

• Antibiotic resistance
• Pseudomonas aeruginosa
• Clinical trial